Effects of care pathways on the in-hospital treatment of heart failure: a systematic review

BMC Cardiovascular Disorders

Massimiliano Panella⁵  Kris Vanhaecht⁵  Ilke Montag³  Erika Milan¹  Antonella Barbieri²  Seval Kul⁴ 

[1]Santa Rita Hospital, Vercelli, Italy

[2]Department of Clinical and Experimental Medicine, University of Eastern Piedmont 'A. Avogadro', Novara, Italy

[3]Center for Health Services and Nursing Research, School of Public Health, Catholic University, Leuven, Belgium

[4]Department of Biostatistics, Faculty of Medicine, University of Gaziantep, Gaziantep, Turkey

[5]European Pathway Association, Leuven, Belgium

关键词: Readmission rate;    Mortality rate;    Length of hospital stay;    Hospitalisation costs;    Heart failure;    Care pathways;   

Others  :  1084368
DOI  :  10.1186/1471-2261-12-81

 received in 2011-09-16, accepted in 2012-09-19,  发布年份 2012

【 摘 要 】

Background

Care pathways have become a popular tool to enhance the quality of care by improving patient outcomes, promoting patient safety, increasing patient satisfaction, and optimizing the use of resources. We performed a disease specific systematic review to determine how care pathways in the hospital treatment of heart failure affect in-hospital mortality, length of in-hospital stay, readmission rate and hospitalisation cost when compared with standard care.

Methods

Medline, Cinahl, Embase and the Cochrane Central Register of Controlled Trials were searched from 1985 to 2010. Each study was assessed independently by two reviewers. Methodological quality of the included studies was assed using the Jadad methodological approach for randomised controlled trials, controlled clinical trials and the New Castle Ottawa Scale for case–control studies, cohort studies and time interrupted series.

Results

Seven studies met the study inclusion criteria and were included in the systematic review with a total sample of 3,690 patients. The combined overall results showed that care pathways have a significant positive effect on mortality and readmission rate. A shorter length of hospital stay was also observed compared with the standard care group. No significant difference was found in the hospitalisation costs. More positive results were observed in controlled trials compared to randomized controlled trials.

Conclusion

By combining all possible results, it can be concluded that care pathways for treatment of heart failure decrease mortality rates and length of hospital stay, but no statistically significant difference was observed in the readmission rates and hospitalisation costs. However, one should be cautious with overall conclusions: what works for one organization may not work for another because of the subtle differences in processes and bottlenecks.

【 授权许可】

   
2012 Kul et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Mcghee G, Murphy E: Research on Reducing Hospitalizations in Patients with Chronic Heart Failure. Home Healthc Nurse 2010, 28:331-340.
• [2]Cowie MR, Fox KF, Wood DA, Metcalfe C, Thompson SG, Coats AJ, Poole-Wilson PA, Sutton GC: Hospitalization of patients with heart failure. A population-based study. Eur Hearth J 2002, 11:877-885.
• [3]American Heart Association: Heart Disease and Stroke Statistics: 2010 Update. A Report from the American Heart Association Statistics Committee and Stroke Statistics. 2009. Published online ahead of print 17
• [4]Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brow M: Projections of the cost of cancer care in the United States 2010–2020. J Natl Cancer Inst 2011, 103:117-128.
• [5]Panella M, Marchisio S, Di Stanislao F: Reducing clinical variations with care pathways: do pathways work? Int J Qual Health Care 2003, 15:509-521.
• [6]Pearson SD, Goulart-Fisher D, Lee TH: Critical pathways as a strategy for improving care: problems and potential. Ann Intern Med 1995, 12:941-948.
• [7]Vanhaecht K, De Witte K, Sermeus W: The impact of care pathways on the organisation of care processes. Leuven: ACCO; 2007.
• [8]Vanhaecht K, Panella M, Sermeus ZR, Sermeus W: An overview on the history and concept of care pathways as complex interventions. Intl J Care Pathw 2010, 14:117-123.
• [9]Lougheed MD, Olajos-Clow JG: Asthma care pathways in the emergency department. Curr Opin Allergy Clin Immunol 2010, 10(3):181-187.
• [10]Panella M, Marchisio S, Demarchi ML, Manzoli L, Stanislao FD: Reduced in-hospital mortality for heart failure with care pathways: the results of a cluster randomised controlled trial. Qual Saf Health Care 2009, 18:369-373.
• [11]Ski CF, Thompson DR: Beyond the blues: the need for integrated care pathways. Eur J Cardiovasc Prev Rehabil 2011, 18(2):218-221.
• [12]Evans-Lacko S, Jarrett M, McCrone P, Thornicroft G: Facilitators and barriers to implementing clinical care pathways. BMC Health Serv Res 2010, 28(10):182.
• [13]Khandaker GM, Gandamaneni PK, Dibben CR, Cherukuru S, Cairns P, Ray MK: Evaluating care pathways for community psychiatry in England: a qualitative study. J Eval Clin Pract 2012. [Epub ahead of print]
• [14]Barbieri A, Vanhaecht K, Van Herck HP, Sermeus W, Faggiano F, Marchisio S, Panella M: Effects of care pathways in the joint replacement: a meta-analysis. BMC Med 2009, 7:32. BioMed Central Full Text
• [15]Neuman MD, Archan S, Karlawish JH, Schwartz JS, Fleisher LA: The relationship between short-term mortality and quality of care for hip fracture: a meta-analysis of care pathways for hip fracture. J Am Geriatr Soc 2009, 57(11):2046-54.
• [16]Van Herck P, Vanhaecht K, Deneckere S, Bellemans J, Panella M, Barbieri A, Sermeus W: Key interventions and outcomes in joint arthroplasty care pathways: a systematic review. J Eval Clin Pract 2010, 16(1):39-49.
• [17]Renholm M, Leino-Kilpi H, Suominen T: Critical pathways. A systematic review. J Nurs Adm 2002, 32(4):196-202.
• [18]Rotter T, Kugler J, Koch R, Gothe H, Twork S, van Oostrum JM, Steyerberg EW: A systematic review and meta-analysis of the effects of care pathways on length of stay, hospital costs and patient outcomes. BMC Health Serv Res 2008, 8:265. BioMed Central Full Text
• [19]Rotter T, Kinsman L, James E, Machotta A, Gothe H, Willis J, Snow P, Kugler J: Care pathways: effects on professional practice, patient outcomes, length of stay and hospital costs. Cochrane Database Syst Rev 2010, 17(3):CD006632.
• [20]Zander K: Integrated care pathways: eleven international trends. J Integr Care Pathways 2002, 6:101-107.
• [21]Cardozo L, Aherns S: Assessing the efficacy of a care pathway in the management of older patients hospitalized with congestive heart failure. J Health Qual 1999, 21(3):12-6.
• [22]Philbin E, Thomas AR, Lindenmuth NW, Ulrich K, McCall M, Jenkins PL: The results of a randomized trial of quality improvement intervention in the care of patients with heart failure. Am J Med 2000, 109:443-449.
• [23]Azad N, Molnar F, Byszewski A: Lessons learned from a multidisciplinary heart failure clinic for older women: a randomised controlled trial. Age Ageing 2008, 37:282-287.
• [24]Lannone P, Lenzi T: Effectiveness of a multipurpose observation unit: before and after study. Emerg Med J 2009, 26:407-414.
• [25]Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ: Assessing the quality of randomized trials: is blinding necessary. Control Clin Trials 1996, 17:1-12.
• [26]Higgins JPT, Green S: ochrane Handbook for Systematic Reviews of Interventions 4.2.5. Chichester, UK: John Wiley & Sons, Ltd: The Cochrane Library; 2005.
• [27]Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
• [28]Discher CL, Klein D, Pierce L, Levine AB, Levine TB: Heart failure disease management: impact on hospital care, length of stay, and reimbursement. Congest Heart Fail 2003, 9(2):77-83.
• [29]Lanzieri M, Hobbs R, Roy P, Richmond R: Use of a clinical care map for the management of congestive heart failure in a community hospital. Clinical Care Map 2001, 7:37-42.
• [30]Rauh RA, Schwabauer RN, Enger EL, Moran JF: A Community hospital-based congestive hearth failure program: Impact on length of stay, admission and readmission rates and cost. Am J Manag Care 1999, 5:37-43.
• [31]Vanhaecht K, Ovretveit J, Elliott MJ, Sermeus W, Ellershaw JE, Panella M: Have we drawn the wrong conclusions about the value of care pathways? Is a cochrane review appropriate? Evaluation & the Health Professional 2011, 35(1):28-42.
• [32]Panella M, Vanhaecht K: Care pathways and organizational systems: the basis for a successful connection. Int J Care Pathways 2010, 15:45-46.
• [33]Petiti DB: Approaches to heterogeneity in meta analysis. Statist Med. 2001, 20:3625-3633.
• [34]Higgins JPT: Commentary: Heterogeneity in meta-analysis International should be expected and appropriately quantified. J Epidemiol 2008, 37:1158-1160.
• [35]Patsopoulos NA, Evangelou E, Ioannidis JPA: Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. Int J Epidemiol 2008, 37:1148-57.
• [36]De Bleser L, Depreitere R, Waele KD, Vanhaecht K, Vlayen J, Sermeus W: Defining pathways. J Nurs Manag 2006, 14(7):553-563.
• [37]Kinsman L, Rotter T, James E, Snow P, Willis J: What is a care pathway? Development of a definition to inform the debate. BMC Med 2010, 8:31. BioMed Central Full Text
• [38]Vanhaecht K: Care Pathways are defined as complex interventions. http://www.biomedcentral.com/1741-7015/8/31/comments webcite (10 October 2012)
• [39]Vanhaecht K, De Witte K, Depreitere R, Sermeus W: Care pathway audit tools: a systematic review. J Nurs Manag 2006, 14(7):529-537.
• [40]Goldmann D: Five puzzle pieces, ten cautionary notes. Int J Care Pathways 2010, 14(1):33-35.
• [41]Hawe P, Shiell A, Riley T, Gold L: Methods for exploring implementation variation and local context within a cluster randomised community intervention trial. J Epidemiol Community Health 2004, 58(9):788-793.
• [42]Berwick DM: The science of ımprovement. JAMA 2008, 299(10):1182-1184.